vs

Side-by-side financial comparison of Immunovant, Inc. (IMVT) and NATIONAL BANKSHARES INC (NKSH). Click either name above to swap in a different company.

NATIONAL BANKSHARES INC is the larger business by last-quarter revenue ($15.3M vs $8.4M, roughly 1.8× Immunovant, Inc.). NATIONAL BANKSHARES INC runs the higher net margin — 38.5% vs -899.0%, a 937.5% gap on every dollar of revenue. On growth, Immunovant, Inc. posted the faster year-over-year revenue change (140.7% vs 24.7%). NATIONAL BANKSHARES INC produced more free cash flow last quarter ($15.2M vs $-59.8M).

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody therapies for patients with serious, rare autoimmune and inflammatory diseases. Its lead product candidate covers multiple autoimmune indications, with core U.S. operations and a global market expansion strategy.

Nicolet Bankshares, Inc. is a U.S. regional bank holding company based in Green Bay, Wisconsin. They are the parent company of Nicolet National Bank, the second largest Wisconsin-based bank.

IMVT vs NKSH — Head-to-Head

Bigger by revenue
NKSH
NKSH
1.8× larger
NKSH
$15.3M
$8.4M
IMVT
Growing faster (revenue YoY)
IMVT
IMVT
+116.1% gap
IMVT
140.7%
24.7%
NKSH
Higher net margin
NKSH
NKSH
937.5% more per $
NKSH
38.5%
-899.0%
IMVT
More free cash flow
NKSH
NKSH
$75.0M more FCF
NKSH
$15.2M
$-59.8M
IMVT

Income Statement — Q4 FY2024 vs Q4 FY2025

Metric
IMVT
IMVT
NKSH
NKSH
Revenue
$8.4M
$15.3M
Net Profit
$-75.3M
$5.9M
Gross Margin
Operating Margin
-896.2%
47.4%
Net Margin
-899.0%
38.5%
Revenue YoY
140.7%
24.7%
Net Profit YoY
-26.7%
91.0%
EPS (diluted)
$-0.50
$0.93

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IMVT
IMVT
NKSH
NKSH
Q4 25
$15.3M
Q3 25
$14.2M
Q2 25
$13.3M
Q1 25
$12.8M
Q4 24
$12.2M
Q3 24
$11.7M
Q2 24
$10.9M
Q1 24
$8.4M
$10.4M
Net Profit
IMVT
IMVT
NKSH
NKSH
Q4 25
$5.9M
Q3 25
$4.4M
Q2 25
$2.3M
Q1 25
$3.2M
Q4 24
$3.1M
Q3 24
$2.7M
Q2 24
$-307.0K
Q1 24
$-75.3M
$2.2M
Operating Margin
IMVT
IMVT
NKSH
NKSH
Q4 25
47.4%
Q3 25
37.9%
Q2 25
20.0%
Q1 25
30.5%
Q4 24
30.1%
Q3 24
27.5%
Q2 24
-4.4%
Q1 24
-896.2%
25.8%
Net Margin
IMVT
IMVT
NKSH
NKSH
Q4 25
38.5%
Q3 25
31.1%
Q2 25
17.2%
Q1 25
25.3%
Q4 24
25.1%
Q3 24
22.8%
Q2 24
-2.8%
Q1 24
-899.0%
20.8%
EPS (diluted)
IMVT
IMVT
NKSH
NKSH
Q4 25
$0.93
Q3 25
$0.69
Q2 25
$0.36
Q1 25
$0.51
Q4 24
$0.50
Q3 24
$0.42
Q2 24
$-0.05
Q1 24
$-0.50
$0.37

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IMVT
IMVT
NKSH
NKSH
Cash + ST InvestmentsLiquidity on hand
$635.4M
$59.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$617.8M
$184.9M
Total Assets
$666.4M
$1.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IMVT
IMVT
NKSH
NKSH
Q4 25
$59.3M
Q3 25
$42.3M
Q2 25
$92.8M
Q1 25
$122.5M
Q4 24
$108.1M
Q3 24
$49.8M
Q2 24
$98.9M
Q1 24
$635.4M
$121.2M
Stockholders' Equity
IMVT
IMVT
NKSH
NKSH
Q4 25
$184.9M
Q3 25
$179.2M
Q2 25
$168.7M
Q1 25
$167.3M
Q4 24
$156.4M
Q3 24
$167.8M
Q2 24
$149.0M
Q1 24
$617.8M
$139.4M
Total Assets
IMVT
IMVT
NKSH
NKSH
Q4 25
$1.8B
Q3 25
$1.8B
Q2 25
$1.8B
Q1 25
$1.8B
Q4 24
$1.8B
Q3 24
$1.8B
Q2 24
$1.8B
Q1 24
$666.4M
$1.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IMVT
IMVT
NKSH
NKSH
Operating Cash FlowLast quarter
$-59.7M
$17.9M
Free Cash FlowOCF − Capex
$-59.8M
$15.2M
FCF MarginFCF / Revenue
-714.4%
99.2%
Capex IntensityCapex / Revenue
1.8%
17.9%
Cash ConversionOCF / Net Profit
3.04×
TTM Free Cash FlowTrailing 4 quarters
$-214.6M
$23.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IMVT
IMVT
NKSH
NKSH
Q4 25
$17.9M
Q3 25
$6.1M
Q2 25
$2.1M
Q1 25
$2.6M
Q4 24
$9.4M
Q3 24
$3.1M
Q2 24
$-3.0M
Q1 24
$-59.7M
$3.8M
Free Cash Flow
IMVT
IMVT
NKSH
NKSH
Q4 25
$15.2M
Q3 25
$5.3M
Q2 25
$1.5M
Q1 25
$1.6M
Q4 24
$6.2M
Q3 24
$2.2M
Q2 24
$-4.0M
Q1 24
$-59.8M
$3.5M
FCF Margin
IMVT
IMVT
NKSH
NKSH
Q4 25
99.2%
Q3 25
37.4%
Q2 25
11.5%
Q1 25
12.5%
Q4 24
50.5%
Q3 24
18.5%
Q2 24
-36.3%
Q1 24
-714.4%
33.8%
Capex Intensity
IMVT
IMVT
NKSH
NKSH
Q4 25
17.9%
Q3 25
5.6%
Q2 25
4.1%
Q1 25
7.5%
Q4 24
26.6%
Q3 24
8.3%
Q2 24
9.3%
Q1 24
1.8%
3.0%
Cash Conversion
IMVT
IMVT
NKSH
NKSH
Q4 25
3.04×
Q3 25
1.38×
Q2 25
0.90×
Q1 25
0.79×
Q4 24
3.07×
Q3 24
1.17×
Q2 24
Q1 24
1.77×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons